Unresolved issues in implantable cardioverter-defibrillator therapy.
Over the last 15 years, a series of well-designed randomized clinical trials has clearly demonstrated that implantable cardioverter-defibrillator (ICD) therapy reduces mortality in select high-risk populations. Despite the widespread acceptance of ICD therapy, many questions related to its optimal use remain. This article discusses several key issues now confronting clinicians.
Mason
Pamela K
PK
Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908, USA. pkm5f@virginia.edu
DiMarco
John P
JP
D017677:Age Distribution; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000453:epidemiology* / Q000628:therapy; D002304:Cardiac Pacing, Artificial / Q000379:methods; D015897:Comorbidity; D016757:Death, Sudden, Cardiac / Q000453:epidemiology* / Q000517:prevention & control*; D017147:Defibrillators, Implantable; D006801:Humans; D010138:Pacemaker, Artificial; D012307:Risk Factors; D014481:United States
D000889:Anti-Arrhythmia Agents